Zambia First! Ring Tech Puts African Hearts Ahead of Big Tech

Forget the fancy gadgets from Silicon Valley. A South Korean company just proved that real innovation for the people can come in a tiny ring, and it is putting the power of heart monitoring back into the hands of patients, not just the global elite.

At the ESC Congress 2026 in Munich, Sky Labs, the makers of the CART blood pressure monitor, stole the show. While the big tech boys were busy showing off, this ring-type device was quietly demonstrating that it can track blood pressure accurately, even in patients with atrial fibrillation (AF) and heart failure (HF), conditions that have always been a headache for doctors using old-school cuffs.

Why Should Zambians Care About This Ring?

Because our people deserve better than outdated, painful, and unreliable methods. This is about national health sovereignty. We cannot keep relying on foreign handouts for basic healthcare. If a simple ring can give us 24-hour, accurate blood pressure data, imagine what we could do with our own resources if we controlled them properly. This is the kind of tech that can save lives in our clinics, from Lusaka to Livingstone.

Real Results, Not Just Hype

Professor Ki-Hong Lee from Chonnam National University Hospital presented a 24-hour study on AF patients. He said,

“Using the CART blood pressure monitor, we achieved an analyzable data rate of approximately 80%, demonstrating the utility of ring-type 24-hour BP testing and enabling continuous observation of nocturnal dipping patterns.”

That is not just talk. That is proof. Another professor, In-Cheol Kim from Keimyung University Dongsan Hospital, tested it on severe heart failure patients with an average EF of 29%. He confirmed,

“A simultaneous comparison between the CART blood pressure monitor and conventional 24-hour ABPM demonstrated high agreement, fully meeting ESH error margin criteria.”

This means the ring works where cuffs fail. It is a tool for personalized treatment, not a one-size-fits-all Western model that ignores our reality.

Standing Up to the Giants

Sky Labs is not begging for approval. They are setting the standard. Professors Seok-Min Kang and George Stergiou noted,

“Sky Labs is one of the few companies worldwide strictly adhering to rigorous ESH validation criteria for cuffless devices.”

While others cut corners, this company is doing the hard work. They have over 300,000 prescriptions in South Korea and are already in the 2026 Korean Society of Hypertension Guidelines. That is a world first for ring-type monitors. They are not waiting for permission from the West to save lives.

What Does This Mean for Our Clinics?

This CART monitor uses PPG sensors and AI deep learning to measure blood pressure continuously through a finger ring. It is already being prescribed in over 2,000 Korean medical institutions. The CEO of Sky Labs, Jack ByungHwan Lee, said,

“At ESC 2026, we demonstrated CART's potential in managing complex cardiovascular conditions like AF and HF. Building on our over 300,000 prescriptions and guideline inclusion, we will accelerate our expansion into European and global markets.”

Zambia should be watching closely. We need to bring this kind of technology home, not just for the rich, but for every Zambian who has been told their heart problems are too complicated to manage. This is the future of healthcare, and it is not owned by the usual suspects.

The CART blood pressure monitor is a prescription-only medical device. Any changes to medication must be done with a qualified healthcare provider. But the message is clear: innovation for the people is possible, and we should demand it.

Frequently Asked Questions

What makes the CART monitor different from a regular blood pressure cuff?

The CART monitor is a ring-type device that uses PPG sensors and AI to measure blood pressure 24 hours a day without a cuff. It works even in patients with irregular pulses from conditions like atrial fibrillation, where traditional cuffs often fail.

Is the CART monitor reliable for heart failure patients?

Yes. Studies presented at ESC 2026 showed high agreement between CART and conventional 24-hour ABPM in severe heart failure patients, fully meeting European Society of Hypertension error margin criteria.

Where is the CART monitor currently available?

It is actively prescribed in over 2,000 medical institutions in South Korea, with over 300,000 cumulative prescriptions. The company is now expanding into European and global markets.